21 May 2013
Keywords: Targacept, AstraZeneca, Alzheimer's disease, Ph IIb, AZD3480
Article | 12 October 2011
US drug developer Targacept (Nasdaq: TRGT) says it has initiated a potential registration study of AZD3480 in mild-to-moderate Alzheimer’ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 October 2011
20 May 2013
© 2013 thepharmaletter.com